2 Under-the-Radar Stocks to Buy and Hold

Axsome reported 2025 revenue up 66% to $638.5M with net loss per share improving to $3.68 from $5.99 in 2024, and management projects late-stage pipeline peak sales above $16B (Auvelity AD agitation peak est. $1.5–$3B). Madrigal, after FDA approval of Rezdiffra, generated $958.4M in 2025 versus $180.1M in 2024 and has treated ~36,250 patients (cited as 17% of its 315,000 specialist-target population). Key risk: Rezdiffra is on accelerated approval and must be confirmed in trials or face removal, but current prescribing trends support commercial uptake.

Analysis

Axsome and Madrigal are playing different optionality games: one is surgical clinical de-risking across neuro/behavioral endpoints where each positive readout compounds valuation, the other is raw market capture in a large metabolic-liver indication where commercial execution and payor acceptance drive near-term cash flow. For Axsome, the principal lever is binary clinical catalysts over the next 12–36 months that can re-rate multiple assets simultaneously; for Madrigal, the lever is penetration of a specialist-to-community prescribing funnel and durability under the accelerated-approval spotlight.

Second-order competitive effects matter: strong early uptake by Madrigal raises the bar for later entrants and creates a short window where incumbency, manufacturing scale, and specialty pharmacy relationships become moat-like — this increases the probability of strategic M&A for fast-moving players. Conversely, Axsome’s successes would force larger neuro-focused pharmas to either partner or accelerate rival programs, concentrating M&A interest but also inviting tighter payer scrutiny on pricing for symptomatic neuro therapies.

Downside vectors are conventional but amplified: confirmatory trial failure or stricter utilization management would be immediate binary shocks (24–48 month horizon), while slower threats include formulary squeezes and rising rebate demands that can compress realized price by tens of percent over 2–3 years. The asymmetric trade is therefore to pay for optionality on clinical upside while capping downside from reimbursement or trial risk via hedges or structured option spreads.

Key Decisions for Investors

• Long MDGL stock with protective puts: buy MDGL shares and buy 12-month 20% OTM puts (or equivalently a collar) to cap downside from confirmatory-trial/regulatory reversals; target 30–60% total return over 12–24 months if adoption continues or M&A occurs, cost ~3–6% of position value for protection.
• Long AXSM via call spread to buy clinical optionality: buy AXSM 18-month LEAP call and sell nearer-term call (vertical spread) to finance premium — size position small (2–3% portfolio) since single pivotal failure can erase value; downside limited to premium, upside concentrated on 12–36 month readouts with potential 2x–5x on success.
• Catalyst pair trade to isolate commercialization vs clinical binary: go long MDGL / short AXSM sized 1:1 (dollar-neutral) for a 6–18 month horizon to benefit if commercial adoption/multiple expansion outpaces binary clinical risk — monitor regulatory headlines weekly and trim if either company reports negative confirmatory data.
• Event hedge for broader biotech volatility: buy a biotech ETF put spread (e.g., 3–6 month DXJL/IBB put spread) sized to cover realized-vol spikes around expected readouts for AXSM to protect portfolio tail risk while keeping upside in single-name long exposures.